Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

Sponsor

National Cancer Institute (NCI) (NIH)

Overall Status

Terminated

CT.gov ID

NCT00070122

Collaborator

(none)

2,200

Enrollment

Location

Arms

Study Details

Study Description

Brief Summary

Drugs used in chemotherapy, such as oxaliplatin, leucovorin, fluorouracil, and capecitabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. It is not yet known which combination chemotherapy regimen with bevacizumab works better in treating colorectal cancer. This randomized phase III trial is studying giving two different combination chemotherapy regimens together with bevacizumab and comparing how well they work in treating patients with locally advanced, metastatic, or recurrent colorectal cancer

Condition or Disease	Intervention/Treatment	Phase
Adenocarcinoma of the Colon Adenocarcinoma of the Rectum Recurrent Colon Cancer Recurrent Rectal Cancer Stage III Colon Cancer Stage III Rectal Cancer Stage IV Colon Cancer Stage IV Rectal Cancer	Drug: oxaliplatin Drug: leucovorin calcium Drug: capecitabine Biological: bevacizumab Drug: fluorouracil Other: laboratory biomarker analysis	Phase 3

Detailed Description

OBJECTIVES:

Compare overall survival in patients with locally advanced, metastatic, or recurrent colorectal cancer treated with fluorouracil, leucovorin calcium, oxaliplatin, and bevacizumab vs capecitabine, oxaliplatin, and bevacizumab.
Compare progression-free survival and time to treatment failure in patients treated with these regimens.
Compare the response of patients with measurable disease treated with these regimens.

IV.Compare toxicity rates of these regimens in these patients. V. Compare patient-reported functional status and convenience of therapy in patients treated with these regimens.

Correlate germline polymorphisms of DNA repair (e.g., ERCC-1, XRCC1, GST-P1, XPD, and ribonucleotide reductase), target enzymes (e.g., thymidylate synthase, dihydropyrimidine dehydrogenase, and thymidine phosphorylase), angiogenesis (e.g., vascular endothelial growth factor), and growth factors (e.g., epithelial growth factor receptor) with survival, progression-free survival, and toxicity from chemotherapy in patients treated with these regimens.
Correlate tumor mRNA expression levels of similar DNA repair enzymes as well as enzymes involved in angiogenesis with survival and progression-free survival in patients treated with these regimens.Correlate tumor mRNA expression levels of similar target enzymes before treatment with survival, progression-free survival, and toxicity in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to Zubrod performance status (0 or 1 vs 2) and prior adjuvant therapy (yes vs no). Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.

ARM II: Patients receive oxaliplatin IV over 2 hours on day 1 and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.

Patients are followed every 3 months until disease progression. After disease progression, patients are followed every 6 months for 2 years and then annually for up to 4 years after study entry.

PROJECTED ACCRUAL: A total of 2,200 patients (1,100 per treatment arm) will be accrued for this study within 3 years.

Study Design

Study Type:

Interventional

Actual Enrollment :

2200 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double (Participant, Investigator)

Primary Purpose:

Treatment

Official Title:

A Phase III Trial of Modified FOLFOX6 Versus CAPOX, With Bevacizumab (NSC-704865) or Placebo, as First-Line Therapy in Patients With Previously Untreated Advanced Colorectal Cancer

Study Start Date :

Apr 1, 2004

Actual Primary Completion Date :

Jan 1, 2007

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Arm I (oxaliplatin, leucovorin calcium, fluorouracil) Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.	Drug: oxaliplatin Given IV Other Names: 1-OHP Dacotin Dacplat Eloxatin L-OHP Drug: leucovorin calcium Given IV Other Names: CF CFR LV Biological: bevacizumab Given IV Other Names: anti-VEGF humanized monoclonal antibody anti-VEGF monoclonal antibody Avastin rhuMAb VEGF Drug: fluorouracil Given IV Other Names: 5-fluorouracil 5-Fluracil 5-FU Other: laboratory biomarker analysis Correlative studies
Experimental: Arm II (oxaliplatin, capecitabine) Patients receive oxaliplatin IV over 2 hours on day 1and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.	Drug: oxaliplatin Given IV Other Names: 1-OHP Dacotin Dacplat Eloxatin L-OHP Drug: capecitabine Given orally Other Names: CAPE Ro 09-1978/000 Xeloda Biological: bevacizumab Given IV Other Names: anti-VEGF humanized monoclonal antibody anti-VEGF monoclonal antibody Avastin rhuMAb VEGF Other: laboratory biomarker analysis Correlative studies

Arm

Intervention/Treatment

Experimental: Arm I (oxaliplatin, leucovorin calcium, fluorouracil)

Patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46-48 hours beginning on day 1. Patients are further randomized to receive bevacizumab or placebo* IV over 30-90 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.

Drug: oxaliplatin

Given IV

Other Names:

1-OHP

Dacotin

Dacplat

Eloxatin

L-OHP

Drug: leucovorin calcium

Given IV

Other Names:

CFR

Biological: bevacizumab

Given IV

Other Names:

anti-VEGF humanized monoclonal antibody

anti-VEGF monoclonal antibody

Avastin

rhuMAb VEGF

Drug: fluorouracil

Given IV

Other Names:

5-fluorouracil

5-Fluracil

5-FU

Other: laboratory biomarker analysis

Correlative studies

Experimental: Arm II (oxaliplatin, capecitabine)

Patients receive oxaliplatin IV over 2 hours on day 1and oral capecitabine on days 1-15. Patients are further randomized to receive bevacizumab or placebo* as in arm I. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity NOTE: *As of 11/15/04, placebo is no longer part of treatment plan; all patients receive bevacizumab.

Drug: oxaliplatin

Given IV

Other Names:

1-OHP

Dacotin

Dacplat

Eloxatin

L-OHP

Drug: capecitabine

Given orally

Other Names:

CAPE

Ro 09-1978/000

Xeloda

Biological: bevacizumab

Given IV

Other Names:

anti-VEGF humanized monoclonal antibody

anti-VEGF monoclonal antibody

Avastin

rhuMAb VEGF

Other: laboratory biomarker analysis

Correlative studies

Outcome Measures

Primary Outcome Measures

Overall survival in patients with colorectal cancer treated with fluorouracil/leucovorin calcium and oxaliplatin with and without becavizumab versus those treated with capecitabine and oxaliplatin with our without bevacizumab [Up to 6 years]
Will be analyzed primarily by the stratified Cox model.

Secondary Outcome Measures

Time to treatment failure [Up to 6 years]
Will be analyzed primarily by the Cox stratified model.
Progression-free survival [Up to 6 years]
Will be analyzed primarily by the Cox stratified model.
Response (among patients with measurable disease) [Up to 6 years]
Will be analyzed primarily by the Cox stratified model.
Treatment toxicities graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE 3.0) [Up to the time of progression]
Change in FACT-C TOI [Baseline to 25 weeks]
The analysis for evaluating this change will be a comparison of the change score between the first and last assessment. If cohort patterns for mean scores do not show signs of informative missing data, a mixed effects linear model approach will be used to measure change in FACT-C TOI scores.
Change in Chemotherapy Convenience and Satisfaction Questionnaire scores [Baseline to 25 weeks]
Effect size will be used to compare the size of the difference in each arm.
Whether gene expression variables are predictive of survival and progression-free survival [Up to 6 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Histologically or cytologically confirmed locally advanced, recurrent, or metastatic colorectal adenocarcinoma
Not curable by surgery or amenable to radiotherapy with curative intent
Previously resected colorectal cancer with new evidence of metastasis does not require separate histologic or cytologic confirmation unless one of the following is true:
More than 5 years has elapsed between primary surgery and development of metastatic disease
Primary tumor was T1-T2, N0, M0
Site of primary lesion must be or have been in the large bowel as determined by endoscopy, radiology, or surgery
Measurable or evaluable disease
No known brain or leptomeningeal disease
Performance status - Zubrod 0-2
No history of hemorrhagic or thrombotic disorders
Absolute neutrophil count greater than 1,500/mm^3
Platelet count greater than 100,000/mm^3
Bilirubin no greater than 2.0 times upper limit of normal (ULN)
SGOT no greater than 2.5 times ULN (5 times ULN for patients with liver involvement)
Alkaline phosphatase no greater than 2.5 times ULN (5 times ULN for patients with liver involvement or 10 times ULN for patients with bone involvement)
INR no greater than 1.5
PTT no greater than ULN
Creatinine no greater than 1.5 times ULN
Creatinine clearance at least 50 mL/min
Proteinuria less than 1+*
Protein less than 500mg/24 hours*
No uncontrolled hypertension
Hypertension must be well-controlled (i.e., less than 160/90) and on a stable regimen of antihypertensive therapy
No unstable angina
No symptomatic congestive heart failure
No myocardial infarction within the past 6 months
No serious uncontrolled cardiac arrhythmia
No New York Heart Association class III or IV heart disease
No symptomatic pulmonary fibrosis
Not pregnant or nursing
Fertile patients must use effective contraception
No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer currently in complete remission
No active or uncontrolled severe infection
No contraindication to oral medications (e.g., severe dysphagia)
G-tubes or J-tubes allowed
No peripheral neuropathy greater than grade 1
No serious non-healing wound, ulcer, or bone fracture
No significant traumatic injury within the past 28 days
No other severe acute or chronic medical condition or laboratory abnormality that would preclude study participation
No psychiatric condition that would preclude study participation
No prior bevacizumab
No prior oxaliplatin
No prior chemotherapy for advanced colorectal cancer
Prior adjuvant therapy for resected stage II-III disease allowed provided at least 12 months have elapsed between completion of therapy and diagnosis of recurrent disease
At least 28 days since prior radiotherapy and recovered
See Disease Characteristics
More than 28 days since prior major surgical procedure or open biopsy
More than 7 days since prior fine needle aspiration or core biopsy
No concurrent major surgery
More than 10 days since prior full-dose aspirin (325 mg)
No concurrent antiplatelet agents (e.g., dipyridamole, ticlopidine, clopidogrel, or cilostazol)
No other concurrent investigational agents
No concurrent therapeutic anticoagulation
Prophylactic anticoagulation of central venous lines allowed
Low-dose prophylactic enoxaparin or heparin allowed
No concurrent cimetidine
No concurrent sorivudine or its related analogs (e.g., brivudine)
No concurrent use of a cold cap or iced mouth rinses